Department of Biomedical Sciences, University of Padova, Padova, Italy.
Istituto di Ricerca Pediatrica (IRP), Fondazione Città della Speranza, Padova, Italy.
Clin Exp Immunol. 2022 Jun 11;208(2):147-157. doi: 10.1093/cei/uxac025.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous subset of cells expanded during multiple pathological settings, including cancers. In tumors, MDSCs are dominant drivers of T-cell immunosuppression. To accomplish their job, they exploit multiple mechanisms ultimately leading to the paralysis of anti-tumor immunity. Among the variety of MDSC-ways of working within the tumor microenvironment, the generation of reactive species and the metabolic reprogramming have emerged as pivotal determinants of their immunosuppressive power. In this review we will overview integral mechanisms of MDSC-mediated immunosuppression in solid tumors, with a particular focus on Non-Hodgkin lymphoma.
髓系来源的抑制细胞(MDSCs)是在多种病理情况下扩增的异质性细胞亚群,包括癌症。在肿瘤中,MDSCs 是 T 细胞免疫抑制的主要驱动因素。为了完成它们的工作,它们利用多种机制,最终导致抗肿瘤免疫的麻痹。在肿瘤微环境中 MDSC 发挥作用的多种方式中,活性物质的产生和代谢重编程已成为其免疫抑制能力的关键决定因素。在这篇综述中,我们将概述 MDSC 介导的实体瘤免疫抑制的完整机制,特别关注非霍奇金淋巴瘤。